Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16881271 | 0.92 | KLKB1 (0.78) | KLKB1MAP4K1 | |
| SCHEMBL16891493 | 0.83 | KLKB1 (0.64) | KLKB1MAP4K1 | |
| SCHEMBL16880705 | 0.81 | KLKB1 (0.88) | KLKB1MAP4K1 | |
| SCHEMBL17442636 | 0.81 | KLKB1 (0.66) | KLKB1MAP4K1 | |
| SCHEMBL17442589 | 0.81 | KLKB1 (0.78) | KLKB1MAP4K1 | |
| SCHEMBL17920379 | 0.80 | KLKB1 (0.84) | KLKB1MAP4K1 | |
| SCHEMBL16880619 | 0.80 | KLKB1 (0.84) | KLKB1MAP4K1 | |
| SCHEMBL17442537 | 0.80 | KLKB1 (0.77) | KLKB1MAP4K1 | |
| SCHEMBL17442564 | 0.79 | KLKB1 (1.00) | KLKB1MAP4K1 | |
| SCHEMBL17442791 | 0.79 | KLKB1 (0.68) | KLKB1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KLKB1 1/4885MAP4K1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.